Additionally, clinical samples from patients with basal-like BCA exhibiting phosphorylated EphA2 (pS897) were found to have the lowest response rates to neoadjuvant treatments and exhibited increased cancer stemness [39]. This evidence concerns the gene EPHA2 and cancer.